Check out this week's QuadCast as we highlight the oncologic benefit of extended nodal dissection for prostate cancer, the comparison of Durvalumab and Cetuximab in cisplatin-ineligible H&N cancer patients, the high incidence of psoriasis development on immunotherapy, and more.
Check out this week's QuadCast as we highlight the oncologic benefit of extended nodal dissection for prostate cancer, the comparison of Durvalumab and Cetuximab in cisplatin-ineligible H&N cancer patients, the high incidence of psoriasis development on immunotherapy, and more.